# PeptideAgent > The peptide agent. Evidence, legality, and access, answered. PeptideAgent answers peptide questions with graded evidence, current regulatory status, and verified access paths. Every claim cites a primary source. PeptideAgent is an editorial reference, not a clinic, pharmacy, or vendor. Every peptide page carries an evidence grade (human RCT, human observational, animal-only, anecdotal, or none), the current United States regulatory status (FDA approval, 503A bulks list, PCAC review, Category 2 removal, or not eligible), WADA status, dosing ranges as reported in the literature only, and numbered primary sources (PubMed, FDA, Federal Register). Editorial review in progress: 0 of 82 peptide records reviewed; unreviewed records are labeled draft on the page. Content is not clinically reviewed and is not medical advice. ## Key pages - [Peptide agent](https://peptideagent.ai/): ask a question, get a graded, sourced answer - [All peptides](https://peptideagent.ai/peptides): index of every peptide by cluster - [Regulatory tracker](https://peptideagent.ai/regulatory): dated FDA, PCAC, Federal Register, and WADA actions - [Regulatory RSS feed](https://peptideagent.ai/regulatory/feed.xml) - [Evidence methodology](https://peptideagent.ai/methodology): how grades, statuses, and dosing ranges are derived - [About](https://peptideagent.ai/about): who publishes this site and what it is not - [Disclaimer](https://peptideagent.ai/disclaimer) - [GLP-1 hub](https://peptideagent.ai/glp-1): every GLP-1 and incretin peptide with evidence, FDA and WADA status, approval and shortage timeline, dated prices, and comparisons - [Peptide blends](https://peptideagent.ai/blends): premixed products sold under nicknames (GLOW, KLOW, Wolverine stack, CJC-1295 and ipamorelin), graded ingredient by ingredient with the strictest legal status of any ingredient - [Zepbound vs Mounjaro](https://peptideagent.ai/glp-1/zepbound-vs-mounjaro): the same drug (tirzepatide) under two FDA labels, with label doses, approved uses, and cost - [Are peptides legal? Peptide laws in all 50 states](https://peptideagent.ai/legal): telehealth rules, pharmacy board, and compounded GLP-1 access for all 50 states plus federal law - [Peptides by condition](https://peptideagent.ai/conditions): peptides studied for each condition, graded, next to the standard of care - [Peptide comparisons](https://peptideagent.ai/compare): head-to-head verdicts with sourced dimensions - [Peptide cost index](https://peptideagent.ai/cost): prices by channel, with and without insurance - [Provider directory](https://peptideagent.ai/providers): verified compounding pharmacies, clinics, and telehealth providers by state; see the [verification checklist](https://peptideagent.ai/providers/verification) - [Compounding pharmacies](https://peptideagent.ai/providers/compounding-pharmacies): how to check a compounding pharmacy, by state - [Clinics](https://peptideagent.ai/providers/clinics): how to check a clinic, by state - [Telehealth providers](https://peptideagent.ai/providers/telehealth): how to check a telehealth provider, by state - [Blog](https://peptideagent.ai/blog): cited news, access guides, and explainers that link to the reference pages - [CJC-1295 side effects: what the human studies reported](https://peptideagent.ai/blog/cjc-1295-side-effects): CJC-1295 side effects in small human studies included injection site reactions, headache, flushing, diarrhea, and a faster heart rate. It has no FDA approval and no lawful compounding path. - [Sermorelin vs HGH: mechanism, evidence, and legal status](https://peptideagent.ai/blog/sermorelin-vs-hgh): Sermorelin signals the pituitary to release growth hormone; HGH (somatropin) is the hormone itself. Only somatropin is FDA approved today, and anti-aging use of either is off-label. - [Tesamorelin vs HGH: how they differ and which is approved](https://peptideagent.ai/blog/tesamorelin-vs-hgh): Tesamorelin (Egrifta) signals the pituitary to release growth hormone and is approved for HIV-associated belly fat; HGH (somatropin) is the hormone itself, approved for other conditions. - [Are peptide injections safe? What is known and unknown](https://peptideagent.ai/blog/are-peptide-injections-safe): FDA-approved peptide injections have documented side effects on their labels. Compounded and research-only peptides add unknowns: sterility, identity, dose accuracy, and contamination. - [Minoxidil side effects: topical, oral, shedding, and pets](https://peptideagent.ai/blog/minoxidil-side-effects): Minoxidil side effects differ by form: scalp irritation and unwanted facial hair with topical use, body hair and fluid retention with oral use. Plus shedding, pregnancy, and the danger to cats. - [Oral minoxidil for hair loss: evidence and side effects](https://peptideagent.ai/blog/oral-minoxidil): Low-dose oral minoxidil is an off-label hair loss treatment. What the FDA label for the blood pressure tablet says, what the hair loss trials found, and the side effects they reported. - [Sildenafil vs Viagra: same drug, generic vs brand](https://peptideagent.ai/blog/sildenafil-vs-viagra): Sildenafil is the active ingredient in Viagra. How generic sildenafil compares, why 20 mg tablets are labeled for pulmonary hypertension, the label side effects, and the nitrate contraindication. - [5-amino-1MQ for fat loss: mouse data, no human trials](https://peptideagent.ai/blog/5-amino-1mq-fat-loss): 5-amino-1MQ reduced fat mass in obese mice, but no human study of any kind has been published. What the mouse studies found, capsules vs injection, side effects, and legal status. - [BPC-157 before and after: reviews, results, and what controlled studies show](https://peptideagent.ai/blog/bpc-157-before-and-after): BPC-157 reviews and before and after stories are everywhere. Controlled results exist only in rats. What the animal healing timelines show, what the human pilots found, and why anecdotes mislead. - [BPC-157 for gut health: the animal evidence and the missing human trials](https://peptideagent.ai/blog/bpc-157-gut-health): BPC-157 healed ulcers, colitis, fistulas, and short bowel in rats. No human gut trial has published results. What the GI studies found, what is missing, and what has human evidence. - [BPC-157 human studies: every published report and registered clinical trial](https://peptideagent.ai/blog/bpc-157-human-studies): Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet. - [BPC-157 nasal spray: what is and is not known about intranasal use](https://peptideagent.ai/blog/bpc-157-nasal-spray): No published study has given BPC-157 as a nasal spray to animals or people. What the one nose-related rat study tested, what a nasal peptide must prove, and its legal status. - [Compounded tirzepatide in 2026: legality, cost, and safety](https://peptideagent.ai/blog/compounded-tirzepatide-guide): The tirzepatide shortage ended in December 2024 and routine compounded copies ended in 2025. What is still lawful, what it cost, FDA safety warnings, and how to check a pharmacy. - [Copper peptides for hair: what the studies show](https://peptideagent.ai/blog/copper-peptides-for-hair): Does GHK-Cu help with hair growth? Copper peptides enlarge hair follicles in lab and mouse studies, but no randomized trial of GHK-Cu alone for hair loss exists. How they compare with minoxidil. - [Do GLP-1 patches work? What they contain and what the evidence says](https://peptideagent.ai/blog/glp-1-patches): No FDA-approved GLP-1 patch exists. Here is why GLP-1 drugs cannot pass through skin from a sticker, what patch ingredients have been tested by mouth, and how to read patch reviews. - [Does tesamorelin build muscle? What the trials show](https://peptideagent.ai/blog/does-tesamorelin-build-muscle): Tesamorelin raised lean body mass about 1.2 kg in HIV trials and slightly increased trunk muscle area, but no trial tested strength or muscle growth, and it is prohibited in sport. - [Epitalon human studies: what the small cohorts actually measured](https://peptideagent.ai/blog/epitalon-human-studies): Most epitalon human data come from one research group and used the pineal extract Epithalamin, not synthetic epitalon. What each study measured, plus the melatonin, telomerase, and cancer questions. - [GLP-1 supplements vs GLP-1 drugs: what GLP-1 boosters actually do](https://peptideagent.ai/blog/glp-1-supplements): Berberine, fiber, and probiotics sold as GLP-1 boosters are not GLP-1 drugs. Here is the human evidence for each ingredient, graded, and how it compares with semaglutide and tirzepatide. - [How to get peptides prescribed legally in 2026](https://peptideagent.ai/blog/how-to-get-peptides-prescribed): Which peptides a licensed prescriber can lawfully write for today, which are waiting on an FDA rule, how telehealth rules work, and the red flags that mean a product is not a prescription at all. - [How to get retatrutide: clinical trials, expanded access, and the law](https://peptideagent.ai/blog/how-to-get-retatrutide): Retatrutide is not approved, so a clinical trial is the only lawful way to get it. How to search ClinicalTrials.gov, how expanded access works, and why online and compounded sources are unlawful. - [Klow vs Glow peptide: what KPV adds and what is known](https://peptideagent.ai/blog/klow-vs-glow): Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend. - [Melanotan 1 before and after: what the afamelanotide trials measured](https://peptideagent.ai/blog/melanotan-1-before-and-after): Melanotan 1 is afamelanotide, approved only as an implant for a rare light sensitivity disease. What the tanning and approval trials measured, what happens to moles, and why tanning use is unapproved. - [Melanotan 2 before and after: what trials and case reports show](https://peptideagent.ai/blog/melanotan-2-before-and-after): Melanotan 2 before and after photos show a tan. Early trials measured it in a few men; case reports since document new moles, melanoma, priapism and FDA safety concerns. - [Microdosing GLP-1s and tirzepatide: what the evidence says](https://peptideagent.ai/blog/microdosing-glp-1-evidence): No trial has tested microdosing semaglutide or tirzepatide. What the labels say about dose steps and why they exist, FDA's dosing-error warnings, and what to ask a prescriber. - [MOTS-c for weight loss: what mouse and human studies show](https://peptideagent.ai/blog/mots-c-weight-loss): MOTS-c prevented diet-induced obesity in mice, but no human trial has tested it for weight loss. What the mouse data show, what human blood studies found, and where it stands legally. - [N-acetyl semax and selank amidate: is there any human data?](https://peptideagent.ai/blog/n-acetyl-semax-and-selank-amidate): What N-terminal acetylation and C-terminal amidation are claimed to change in semax and selank, what the lab studies actually found, and why no human study has tested either modified version. - [Oral BPC-157: what capsules and pills were tested for, and what is missing](https://peptideagent.ai/blog/oral-bpc-157): Oral BPC-157 worked in rat gut, ligament, and fistula studies. No study has measured how much an oral capsule absorbs in people, and the two registered oral studies have posted no results. - [Peptide before and after: trial results vs marketing photos](https://peptideagent.ai/blog/peptide-before-and-after): Measured peptide before and after results: GLP-1 weight change, tesamorelin visceral fat, and regain after stopping, compared with Glow, GHK-Cu, BPC-157, and Wolverine claims. - [Peptide stacks: what each common component has shown alone](https://peptideagent.ai/blog/peptide-stacks): No trial has tested a multi-peptide stack for muscle growth or fat loss. Nine common stack components ranked by their own human evidence, legal status, and WADA status. No protocols. - [Peptides for men, ranked by human evidence](https://peptideagent.ai/blog/peptides-for-men): hCG, GLP-1 drugs, teriparatide, and tesamorelin have human trials and a lawful route. PT-141 is off-label for men, and kisspeptin and melanotan II have no lawful path. Ranking, legality, and WADA. - [Peptides for muscle growth, ranked by human evidence](https://peptideagent.ai/blog/peptides-for-muscle-growth-ranked): MK-677, sermorelin, tesamorelin, CJC-1295, IGF-1 LR3, and more ranked by human evidence. None is approved for muscle growth, and all ten are banned in tested sport. - [Peptides for weight loss, ranked by human evidence](https://peptideagent.ai/blog/peptides-for-weight-loss-ranked): Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices. - [Peptides for women, ranked by human evidence](https://peptideagent.ai/blog/peptides-for-women): GLP-1 drugs, teriparatide, abaloparatide, and Vyleesi (PT-141) have real trials in women. Kisspeptin is research-only and GHK-Cu rests on small skin studies. The ranking and legal status. - [Retatrutide before and after: weight loss by dose and week in the trials](https://peptideagent.ai/blog/retatrutide-before-and-after): What retatrutide trials measured: 24.2% mean weight loss at 48 weeks in phase 2, up to 28.3% at 80 weeks in phase 3, and what happened to fat, waist size, and blood sugar. - [Retatrutide benefits beyond weight loss: liver fat, blood sugar, and blood pressure](https://peptideagent.ai/blog/retatrutide-benefits): What retatrutide trials measured besides weight: liver fat, HbA1c, blood pressure, lipids, fat mass, and knee pain. What is proven, what is post hoc, and what is still unknown. - [Retatrutide side effects: what the trials reported, dose by dose](https://peptideagent.ai/blog/retatrutide-side-effects): Nausea, diarrhea, dysesthesia, heart rate, and dropouts in the retatrutide trials, with placebo rates. What the data say about safety, and what is still unknown. - [Selank nasal spray: the evidence, and combining it with semax](https://peptideagent.ai/blog/selank-nasal-spray): What the intranasal selank studies measured, whether the route matters, and what is known about semax and selank nasal spray together: no trial has tested the combination. - [Selank withdrawal: dependence, benzodiazepines, and alcohol](https://peptideagent.ai/blog/selank-withdrawal): Does selank cause withdrawal? What studies measured on dependence, how it compares with benzodiazepines, the rodent alcohol and opioid withdrawal studies, and the untested alcohol interaction. - [Semax nasal spray: what the intranasal studies show](https://peptideagent.ai/blog/semax-nasal-spray): Semax was developed in Russia as nasal drops. What the intranasal stroke and imaging studies measured, how nasal and injected data compare, and what the July 2026 PCAC vote means. - [TB-500 vs thymosin beta-4: is it the same peptide?](https://peptideagent.ai/blog/tb-500-vs-thymosin-beta-4): TB-500 is not the same molecule as thymosin beta-4. What each one is, which has human data, what is known about capsules and sprays, and what the evidence says about cancer. - [Tesamorelin before and after: what the trials measured](https://peptideagent.ai/blog/tesamorelin-before-and-after): Tesamorelin results from the 26 and 52 week trials: about 15 to 18% less visceral fat, little change in weight, and fat that came back after stopping. Why photos are not trial data. - [Tesamorelin prescription: who qualifies and how to get one](https://peptideagent.ai/blog/tesamorelin-prescription): How to get tesamorelin legally: who qualifies for Egrifta WR on label, how off-label prescribing works, why compounded tesamorelin is not lawful, what a visit should check, and cost. - [Tesamorelin vs sermorelin vs ipamorelin: evidence and legality](https://peptideagent.ai/blog/tesamorelin-vs-sermorelin-vs-ipamorelin): Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison. - [Thymosin alpha-1 access: approved abroad, not in the US](https://peptideagent.ai/blog/thymosin-alpha-1-access): Thymosin alpha-1 is approved as Zadaxin in more than 30 countries but has never been FDA approved, and US compounding has no lawful basis. What that means for access, forms, and thymalin. - [Topical vs injectable GHK-Cu: what the evidence shows](https://peptideagent.ai/blog/topical-vs-injectable-ghk-cu): Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and no lawful compounding path. Evidence, absorption, safety, and legality compared. - [What is peptide therapy? What clinics sell, what is legal, and what works](https://peptideagent.ai/blog/what-is-peptide-therapy): Peptide therapy means three different things: FDA-approved drugs, compounded prescriptions, and research-only products. Here is how to tell them apart, what the evidence shows, and what it costs. - [Can you get a GLP-1 through telehealth in your state?](https://peptideagent.ai/blog/glp-1-telehealth-by-state): Yes in every state, but the rules for the visit, the prescriber's license, and the pharmacy differ. How state telehealth law shapes GLP-1 access, with ten state examples. - [GLP-1 side effects ranked by trial frequency](https://peptideagent.ai/blog/glp-1-side-effects-ranked): Nausea tops the list, but the label warnings matter more. Side effects of semaglutide and tirzepatide ranked by how often they occurred in the trials, with placebo rates for context. - [How to get a compounded GLP-1 prescription in 2026](https://peptideagent.ai/blog/compounded-glp1-prescription-2026): Compounded semaglutide and tirzepatide are now limited to documented patient-specific needs. Here is how the lawful path works, how to check a pharmacy, and what the branded alternatives cost. - [How to read a peptide study](https://peptideagent.ai/blog/how-to-read-a-peptide-study): A practical checklist for judging peptide research: who was studied, how it was designed, what was measured, and whether it was replicated. Worked through with real studies. - [PCAC recommended six peptides. What changes and what does not](https://peptideagent.ai/blog/pcac-vote-six-peptides): FDA's compounding advisory committee backed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list and rejected DSIP. Here is what the vote does and does not do. - [Peptides for tendon recovery, ranked by human evidence](https://peptideagent.ai/blog/peptides-for-tendon-recovery-ranked): BPC-157, TB-500, GHK-Cu, PEG-MGF, and IGF-1 LR3 ranked by our evidence grades. None has a published human tendon trial. Here is the ranking, the reasoning, and what does have human data. - [Retatrutide: where the phase 3 program stands](https://peptideagent.ai/blog/retatrutide-phase-3-status): Five phase 3 readouts, one peer-reviewed paper, and no approval yet. What the retatrutide trials have shown, what is still pending, and why no one can lawfully sell it today. - [SURMOUNT-5 explained: tirzepatide vs semaglutide head to head](https://peptideagent.ai/blog/surmount-5-explained): The first head-to-head obesity trial of tirzepatide and semaglutide found a 20.2% vs 13.7% weight loss gap at 72 weeks. What it tested, what it did not, and what it means for access. - [Wegovy pill vs injection: what the trials show](https://peptideagent.ai/blog/oral-vs-injectable-semaglutide): Semaglutide now comes as a daily tablet and a weekly injection for weight management. We compare the trials, the label differences, and what each costs to get. - [What are peptides? A plain-English guide](https://peptideagent.ai/blog/what-are-peptides): Peptides are short chains of amino acids. Some are FDA approved medicines, some are compounded, and many are unapproved research chemicals. Here is how to tell them apart. - [What happened to compounded semaglutide](https://peptideagent.ai/blog/what-happened-to-compounded-semaglutide): Compounded semaglutide went from a shortage workaround to a narrow, patient-specific exception. Here is the timeline, what FDA found, and what access looks like in 2026. - [Blog RSS feed](https://peptideagent.ai/blog/feed.xml) - [Developers](https://peptideagent.ai/developers): free public JSON API (v1) with an OpenAPI document at https://peptideagent.ai/api/v1/openapi.json - [Open data](https://peptideagent.ai/data): downloadable datasets (JSON and CSV, CC BY 4.0) - [peptides.json](https://peptideagent.ai/datasets/peptides.json): Peptides - [peptides.csv](https://peptideagent.ai/datasets/peptides.csv): Peptides (flat) - [regulatory-events.json](https://peptideagent.ai/datasets/regulatory-events.json): Regulatory events - [regulatory-events.csv](https://peptideagent.ai/datasets/regulatory-events.csv): Regulatory events (flat) - [jurisdictions.json](https://peptideagent.ai/datasets/jurisdictions.json): Jurisdictions - [comparisons.json](https://peptideagent.ai/datasets/comparisons.json): Comparisons - [LICENSE.txt](https://peptideagent.ai/datasets/LICENSE.txt): License - [README.md](https://peptideagent.ai/datasets/README.md): Readme - [State of Peptides, 2026 Q3](https://peptideagent.ai/data/state-of-peptides-2026-q3): quarterly report with a regulatory scorecard, evidence grades by cluster, a dated cash price index, FAERS adverse event trends, and state telehealth access, with CSV downloads - [Press release](https://peptideagent.ai/data/state-of-peptides-2026-q3/press): headline figures and methodology summary - [regulatory-scorecard.csv](https://peptideagent.ai/datasets/reports/state-of-peptides-2026-q3/regulatory-scorecard.csv): Regulatory scorecard - [regulatory-events-2026.csv](https://peptideagent.ai/datasets/reports/state-of-peptides-2026-q3/regulatory-events-2026.csv): 2026 regulatory events - [evidence-by-cluster.csv](https://peptideagent.ai/datasets/reports/state-of-peptides-2026-q3/evidence-by-cluster.csv): Evidence grade by cluster - [price-index.csv](https://peptideagent.ai/datasets/reports/state-of-peptides-2026-q3/price-index.csv): Compounded and cash price index - [faers-reports-by-year.csv](https://peptideagent.ai/datasets/reports/state-of-peptides-2026-q3/faers-reports-by-year.csv): FAERS reports by year - [faers-top-reactions.csv](https://peptideagent.ai/datasets/reports/state-of-peptides-2026-q3/faers-top-reactions.csv): FAERS top reported reactions - [state-access.csv](https://peptideagent.ai/datasets/reports/state-of-peptides-2026-q3/state-access.csv): State access map - [Press and media kit](https://peptideagent.ai/press): citable statistics, logo files, boilerplate, and citation guidance - [Newsletter](https://peptideagent.ai/newsletter): regulatory email alerts - [Sitemap](https://peptideagent.ai/sitemap.xml) ## Peptides Each line: name, evidence grade, FDA status, one-line summary. Peptides marked coverage in progress are in the launch set but do not have a published record yet. ### GLP-1 and incretin agonists - [Semaglutide](https://peptideagent.ai/peptides/semaglutide): Human RCT evidence; FDA approved. FDA approved GLP-1 agonist with about 15% average weight loss in a 68 week RCT and proven cardiovascular benefit. - [Tirzepatide](https://peptideagent.ai/peptides/tirzepatide): Human RCT evidence; FDA approved. FDA approved weekly GIP and GLP-1 drug with 20.9% average weight loss at 15 mg in a 72 week randomized trial; beat semaglutide head to head. - [Liraglutide](https://peptideagent.ai/peptides/liraglutide): Human RCT evidence; FDA approved. First daily GLP-1 drug: FDA approved since 2010, about 8% weight loss at 3 mg over 56 weeks, proven heart benefit, now available as a generic. - [Retatrutide](https://peptideagent.ai/peptides/retatrutide): Human RCT evidence; Not eligible for compounding. Investigational triple agonist, nicknamed reta or GLP-3, with 24.2% weight loss at 48 weeks in phase 2 and 28.3% in a phase 3 topline; not FDA approved. - [Cagrilintide](https://peptideagent.ai/peptides/cagrilintide): Human RCT evidence; Not eligible for compounding. Experimental weekly copy of the appetite hormone amylin: 10.8% weight loss alone at 26 weeks and 20.4% with semaglutide at 68 weeks; not FDA approved. - [Dulaglutide](https://peptideagent.ai/peptides/dulaglutide): Human RCT evidence; FDA approved. FDA approved weekly GLP-1 drug for type 2 diabetes that cut heart attacks, strokes, and heart deaths by 12% over 5.4 years in REWIND; not for weight loss. - [Exenatide](https://peptideagent.ai/peptides/exenatide): Human RCT evidence; FDA approved. The first GLP-1 drug, FDA approved in 2005; lowers HbA1c (3 month blood sugar) 0.8 to 1.9 points with 2 to 4 kg weight loss; no proven heart benefit. - [Survodutide](https://peptideagent.ai/peptides/survodutide): Human RCT evidence; Not eligible for compounding. Investigational glucagon/GLP-1 dual agonist: 13% weight loss at 76 weeks in phase 3 and strong liver (MASH) data, but not FDA approved. - [Mazdutide](https://peptideagent.ai/peptides/mazdutide): Human RCT evidence; Not eligible for compounding. GLP-1/glucagon dual agonist with 14% weight loss at 48 weeks in a Chinese phase 3 trial and 18% at 16 mg in a US phase 2; not FDA approved. ### Tissue repair and healing - [BPC-157](https://peptideagent.ai/peptides/bpc-157): Animal-only evidence; Under FDA review. A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a shifting FDA compounding status. - [TB-500 (thymosin beta-4)](https://peptideagent.ai/peptides/tb-500): Animal-only evidence; Under FDA review. Copy or fragment of the repair protein thymosin beta-4: strong animal data, small human trials of the full protein, no trial of injected TB-500; WADA banned. - [GHK-Cu](https://peptideagent.ai/peptides/ghk-cu): Human observational evidence; Removed from Category 2 (Apr 2026). Copper binding three amino acid peptide with decades of skin and wound data: lawful and well studied in skin cosmetics, unapproved and untested as an injection. - [KPV](https://peptideagent.ai/peptides/kpv): Animal-only evidence; Under FDA review. Anti-inflammatory fragment of the hormone alpha-MSH; mouse colitis data, no human trial; recommended for FDA's compounding list in July 2026, rule pending. - [PEG-MGF](https://peptideagent.ai/peptides/peg-mgf): Animal-only evidence; Removed from Category 2 (Apr 2026). PEG-coated fragment of a muscle form of the growth factor IGF-1: cell and mouse data only, no human trial of the peptide, and named on WADA's banned list. - [ARA-290 (cibinetide)](https://peptideagent.ai/peptides/ara-290): Human RCT evidence; Not eligible for compounding. Erythropoietin derived peptide with small placebo controlled trials in sarcoidosis and diabetic neuropathy; investigational, not approved, WADA prohibited. - [IGF-1 LR3](https://peptideagent.ai/peptides/igf-1-lr3): Animal-only evidence; Unscheduled. Lab research version of the growth factor IGF-1, 2 to 3 times more potent than IGF-1 in rats; no human study, not FDA approved, banned by WADA under S2. - [Follistatin-344](https://peptideagent.ai/peptides/follistatin-344): Animal-only evidence; Unscheduled. Protein that blocks myostatin, the body's muscle growth brake: big gains in mice and monkeys; human data only from gene therapy, not injections; WADA banned. - [ACE-031 (ramatercept)](https://peptideagent.ai/peptides/ace-031): Human RCT evidence; Unscheduled. A myostatin blocking fusion protein that grew lean mass in a small human trial but was abandoned after bleeding side effects in boys with DMD. ### Longevity and mitochondrial - [Epitalon](https://peptideagent.ai/peptides/epitalon): Animal-only evidence; Under FDA review. 4 amino acid peptide from a pineal gland extract: telomere and lifespan data in cells and mice, small non-randomized Russian human reports, not FDA approved. - [MOTS-c](https://peptideagent.ai/peptides/mots-c): Animal-only evidence; Under FDA review. A 16 amino acid peptide coded by mitochondrial DNA that improves metabolism and exercise capacity in mice; human data limited to blood levels and genetics. - [Humanin](https://peptideagent.ai/peptides/humanin): Animal-only evidence; Unscheduled. A 24 amino acid peptide coded by mitochondrial DNA, protective in cells and rodents and tied to blood levels in people; no human treatment trials. - [SS-31 (elamipretide)](https://peptideagent.ai/peptides/ss-31): Human RCT evidence; FDA approved. Mitochondria targeted peptide FDA approved in 2025 as Forzinity for rare Barth syndrome, after a large mitochondrial muscle disease RCT missed its main goal. - [NAD+](https://peptideagent.ai/peptides/nad-plus): Human RCT evidence; Under FDA review. A coenzyme, not a peptide, whose precursors raise blood NAD+ in human RCTs; clinical benefits and IV NAD+ itself remain largely unproven. - [FOXO4-DRI](https://peptideagent.ai/peptides/foxo4-dri): Animal-only evidence; Unscheduled. A senolytic peptide that clears senescent cells and restored fitness, fur, and kidney function in aged mice; no human data exist. - [Thymalin](https://peptideagent.ai/peptides/thymalin): Human observational evidence; Unscheduled. A Russian calf thymus peptide extract used to adjust the immune system, with decades of non-randomized Russian reports and no FDA review. - [Carnosine](https://peptideagent.ai/peptides/carnosine): Human RCT evidence; Unscheduled. A natural muscle dipeptide with small human RCTs showing modest glycemic and waist benefits; a lawful supplement, not a drug. - [Glutathione](https://peptideagent.ai/peptides/glutathione): Human RCT evidence; Under FDA review. The body's main antioxidant tripeptide; one RCT shows oral doses raise body stores, clinical benefit is unproven, and IV use is compounded pending an FDA rule. ### Cognitive and neuroprotective - [Semax](https://peptideagent.ai/peptides/semax): Human observational evidence; Under FDA review. Nasal peptide registered in Russia; rodent brain growth factor data and open label Russian stroke trials; not FDA approved; recommended for compounding in 2026. - [Selank](https://peptideagent.ai/peptides/selank): Human observational evidence; Removed from Category 2 (Apr 2026). Anti-anxiety nasal peptide registered in Russia, with small open label trials against a benzodiazepine; not FDA approved and not on FDA advisers' 2026 list. - [Dihexa](https://peptideagent.ai/peptides/dihexa): Animal-only evidence; Removed from Category 2 (Apr 2026). Oral lab-made relative of the brain peptide angiotensin IV: rat memory data from one lab, a retracted mechanism paper, no human trials, no FDA approval. - [Cerebrolysin](https://peptideagent.ai/peptides/cerebrolysin): Human RCT evidence; Unscheduled. Porcine brain peptide mixture with several RCTs in stroke and dementia, mixed and low certainty results, approved in some countries but not by FDA. - [P21](https://peptideagent.ai/peptides/p21): Animal-only evidence; Unscheduled. Lab-made peptide mimicking part of CNTF, a protein that keeps nerve cells alive; mouse and rat memory and Alzheimer data; no human studies of any kind. - [Noopept](https://peptideagent.ai/peptides/noopept): Human observational evidence; Unscheduled. A dipeptide-like memory drug approved in Russia, with small open-label human studies, no placebo-controlled RCT indexed in English, and no FDA review. - [Pinealon](https://peptideagent.ai/peptides/pinealon): Animal-only evidence; Unscheduled. Three amino acid peptide from Russia's Khavinson bioregulator family, sold there as a brain supplement; rat and cell data only, no controlled human trial. ### Sexual health and reproductive - [PT-141 (bremelanotide)](https://peptideagent.ai/peptides/pt-141): Human RCT evidence; FDA approved. FDA approved (Vyleesi, 2019) for low sexual desire in premenopausal women; effect is small and nausea affects about 40% of users. - [Kisspeptin-10](https://peptideagent.ai/peptides/kisspeptin-10): Human observational evidence; Not eligible for compounding. Fragment of a brain hormone that raises LH and testosterone in small human studies; still on FDA's 503A Category 2 safety risk list, so it cannot be compounded. - [Oxytocin](https://peptideagent.ai/peptides/oxytocin): Human RCT evidence; FDA approved. FDA approved injectable (Pitocin) for labor and postpartum bleeding; intranasal use for bonding, libido, or autism rests on small, mixed trials. - [Melanotan II](https://peptideagent.ai/peptides/melanotan-ii): Human RCT evidence; Removed from Category 2 (Apr 2026). Unapproved tanning and libido injection with two tiny 1990s erection trials, case reports of melanoma and prolonged erections, and no lawful source. - [Melanotan I (afamelanotide)](https://peptideagent.ai/peptides/melanotan-i): Human RCT evidence; FDA approved. FDA approved implant (Scenesse, 2019) that lets people with erythropoietic protoporphyria tolerate sunlight; not approved or sold for tanning. - [Gonadorelin](https://peptideagent.ai/peptides/gonadorelin): Human observational evidence; FDA approved. Native GnRH: proven when pumped in pulses for hypothalamic infertility, unstudied as the 2 to 3 times weekly TRT add-on clinics now sell. - [HCG (human chorionic gonadotropin)](https://peptideagent.ai/peptides/hcg): Human RCT evidence; FDA approved. FDA approved hormone for infertility and male hypogonadism; useless for weight loss and no longer compoundable since it became a biologic in 2020. ### Metabolic and growth hormone axis - [Tesamorelin](https://peptideagent.ai/peptides/tesamorelin): Human RCT evidence; FDA approved. FDA approved lab-made growth hormone releasing hormone (Egrifta, 2010) that cuts deep belly fat about 15% in HIV lipodystrophy and cut liver fat in a trial. - [Sermorelin](https://peptideagent.ai/peptides/sermorelin): Human RCT evidence; Regulatory status unknown. Formerly FDA approved piece of growth hormone releasing hormone (Geref, withdrawn 2009 for business reasons); small trials show higher GH and IGF-1. - [Ipamorelin](https://peptideagent.ai/peptides/ipamorelin): Animal-only evidence; Removed from Category 2 (Apr 2026). Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; raised GH in animals and one small study in men; its only randomized trial failed. - [CJC-1295](https://peptideagent.ai/peptides/cjc-1295): Human RCT evidence; Removed from Category 2 (Apr 2026). Long acting lab-made growth hormone releasing hormone: small randomized trials raised GH 2 to 10 fold and IGF-1 1.5 to 3 fold per dose; no lawful compounding. - [GHRP-2](https://peptideagent.ai/peptides/ghrp-2): Human observational evidence; Not eligible for compounding. Lab-made peptide that triggers growth hormone through the hunger hormone (ghrelin) receptor; approved only as a diagnostic test in Japan; WADA prohibited. - [GHRP-6](https://peptideagent.ai/peptides/ghrp-6): Human observational evidence; Not eligible for compounding. Original lab-made growth hormone releasing peptide: raises GH and hunger in small human studies; never approved; on an FDA compounding risk list; WADA banned. - [Hexarelin](https://peptideagent.ai/peptides/hexarelin): Human observational evidence; Unscheduled. Potent lab-made growth hormone releaser with 1990s human data; the GH response fades with repeated use; never approved anywhere; WADA prohibited. - [MK-677 (ibutamoren)](https://peptideagent.ai/peptides/mk-677): Human RCT evidence; Not eligible for compounding. Oral ghrelin mimetic with real RCTs: raises IGF-1 and lean mass modestly, raises glucose and appetite, a heart failure signal stopped development. Not approved. - [AOD-9604](https://peptideagent.ai/peptides/aod-9604): Animal-only evidence; Removed from Category 2 (Apr 2026). Growth hormone fragment that raised fat burning in obese mice; no human trial in PubMed shows weight loss; FDA nomination withdrawn; banned by WADA. - [Tesofensine](https://peptideagent.ai/peptides/tesofensine): Human RCT evidence; Unscheduled. Not a peptide: an oral triple reuptake inhibitor that produced about 10% placebo adjusted weight loss over 24 weeks in a phase 2 RCT. Not FDA approved. - [5-Amino-1MQ](https://peptideagent.ai/peptides/5-amino-1mq): Animal-only evidence; Unscheduled. Not a peptide: an oral blocker of NNMT, an enzyme overactive in fat tissue, that cut fat in obese mice; no human trial published; not approved or compoundable. - [Adipotide](https://peptideagent.ai/peptides/adipotide): Animal-only evidence; Unscheduled. Experimental peptide that kills blood vessels feeding white fat; 11% weight loss in obese monkeys with kidney damage; no human results published. - [Setmelanotide](https://peptideagent.ai/peptides/setmelanotide): Human RCT evidence; FDA approved. FDA approved hunger-pathway (MC4R) drug for rare genetic obesity (POMC, PCSK1, LEPR, Bardet-Biedl) and acquired hypothalamic obesity; not for common obesity. - [Pramlintide](https://peptideagent.ai/peptides/pramlintide): Human RCT evidence; FDA approved. FDA approved lab-made amylin used with mealtime insulin; lowers HbA1c about 0.3 to 0.4 points more than placebo, modest weight loss, boxed low sugar warning. - [Insulin](https://peptideagent.ai/peptides/insulin): Human RCT evidence; FDA approved. The original peptide drug: FDA approved since 1923, essential in type 1 diabetes, proven to cut complications by 25 to 76%; WADA banned without an exemption. - [Glucagon](https://peptideagent.ai/peptides/glucagon): Human RCT evidence; FDA approved. FDA approved rescue hormone for severe low blood sugar; injection, nasal powder, autoinjector, and dasiglucagon restore glucose in about 10 to 15 minutes. ### Immune and antimicrobial - [Thymosin alpha-1](https://peptideagent.ai/peptides/thymosin-alpha-1): Human RCT evidence; Removed from Category 2 (Apr 2026). Immune modulating thymus peptide approved abroad (not the US) for hepatitis B and as a vaccine booster; mixed sepsis trials; FDA nomination withdrawn. - [Thymulin](https://peptideagent.ai/peptides/thymulin): Human RCT evidence; Unscheduled. Zinc dependent thymus hormone (9 amino acids) with 1980s rheumatoid arthritis trials and rodent anti-inflammatory data; never approved, never nominated to FDA. - [LL-37](https://peptideagent.ai/peptides/ll-37): Human RCT evidence; Removed from Category 2 (Apr 2026). The only human cathelicidin, a germ-killing peptide. A skin gel had two small leg ulcer RCTs; no human data for injections. Off FDA Category 2 since April 2026. - [VIP (vasoactive intestinal peptide)](https://peptideagent.ai/peptides/vip): Human RCT evidence; Under FDA review. Natural nerve signaling peptide; small trials in lung artery hypertension and COVID-19 breathing failure showed no benefit; not FDA approved; FDA Category 1. - [PNC-27](https://peptideagent.ai/peptides/pnc-27): Animal-only evidence; Unscheduled. A lab-stage anticancer peptide tested only in lab-dish cells and mice; no human trials; FDA has warned patients not to use PNC-27 products sold online. ### Other peptides - [DSIP (delta sleep-inducing peptide)](https://peptideagent.ai/peptides/dsip): Human RCT evidence; Not eligible for compounding. A 9 amino acid peptide with small, mixed 1980s insomnia trials; off FDA's Category 2 risk list since April 2026 but rejected by FDA advisers in July 2026. - [Teriparatide](https://peptideagent.ai/peptides/teriparatide): Human RCT evidence; FDA approved. FDA approved daily osteoporosis injection that cut new spine fractures by 65% in its pivotal trial and beat risedronate head to head. - [Abaloparatide](https://peptideagent.ai/peptides/abaloparatide): Human RCT evidence; FDA approved. FDA approved daily osteoporosis injection that cut new spine fractures by 86% versus placebo (a dummy injection) in the 2,463 patient ACTIVE trial. - [Octreotide](https://peptideagent.ai/peptides/octreotide): Human RCT evidence; FDA approved. FDA approved since 1988 for acromegaly and carcinoid syndrome; the randomized PROMID trial showed it slows midgut neuroendocrine tumor growth (HR 0.34). - [Lanreotide](https://peptideagent.ai/peptides/lanreotide): Human RCT evidence; FDA approved. FDA approved monthly copy of the hormone somatostatin for acromegaly and neuroendocrine tumors; halved tumor progression risk in the CLARINET trial (HR 0.47). - [Leuprolide](https://peptideagent.ai/peptides/leuprolide): Human RCT evidence; FDA approved. FDA approved since 1985; after a brief surge it shuts down testosterone or estrogen; standard therapy for prostate cancer, endometriosis, and early puberty. - [Triptorelin](https://peptideagent.ai/peptides/triptorelin): Human RCT evidence; FDA approved. FDA approved depot shot that shuts off sex hormones, for advanced prostate cancer (2000) and early puberty (2017); matched leuprolide in a 284 patient trial. - [Degarelix](https://peptideagent.ai/peptides/degarelix): Human RCT evidence; FDA approved. FDA approved GnRH blocker for advanced prostate cancer: castrate testosterone in 3 days with no flare, held in 97 to 98% at 1 year in a 610 patient trial. - [Vasopressin](https://peptideagent.ai/peptides/vasopressin): Human RCT evidence; FDA approved. Natural pituitary hormone, FDA approved as an ICU drug to raise blood pressure in shock; the 778 patient VASST trial found no survival gain over norepinephrine. - [Desmopressin](https://peptideagent.ai/peptides/desmopressin): Human RCT evidence; FDA approved. FDA approved since 1978 for central diabetes insipidus, bleeding disorders, bedwetting, and nighttime urination; boxed warning for low blood sodium. - [Calcitonin](https://peptideagent.ai/peptides/calcitonin): Human RCT evidence; FDA approved. FDA approved salmon calcitonin for Paget disease, high blood calcium, and osteoporosis; weak fracture data and a 2013 cancer signal restricted its use. - [Linaclotide](https://peptideagent.ai/peptides/linaclotide): Human RCT evidence; FDA approved. FDA approved capsule for irritable bowel syndrome with constipation (IBS-C) and chronic constipation; about 34% respond versus 14% to 21% on placebo. - [Ziconotide](https://peptideagent.ai/peptides/ziconotide): Human RCT evidence; FDA approved. FDA approved non-opioid painkiller infused into spinal fluid for severe chronic pain; works for a minority; boxed warning for psychiatric effects. - [Enfuvirtide](https://peptideagent.ai/peptides/enfuvirtide): Human RCT evidence; FDA approved. FDA approved HIV injection that stops the virus entering cells, for drug-resistant HIV; cuts viral load an extra 0.8 to 0.9 log10 (6 to 8 fold) at 24 weeks. - [Vosoritide](https://peptideagent.ai/peptides/vosoritide): Human RCT evidence; FDA approved. FDA approved daily injection for achondroplasia that increases growth velocity by about 1.6 cm per year over placebo in children. - [Terlipressin](https://peptideagent.ai/peptides/terlipressin): Human RCT evidence; FDA approved. FDA approved hospital IV drug for hepatorenal syndrome (kidney failure from advanced liver disease); reverses it in about 32% versus 17% with albumin alone. - [Cosyntropin](https://peptideagent.ai/peptides/cosyntropin): Human observational evidence; FDA approved. FDA approved diagnostic peptide for the ACTH stimulation test, which checks whether the adrenal glands make enough cortisol; prohibited by WADA in sport. - [Ganirelix](https://peptideagent.ai/peptides/ganirelix): Human RCT evidence; FDA approved. FDA approved daily IVF injection that blocks early ovulation; live birth rates equal to older protocols with about 40% less ovarian overstimulation. - [Cetrorelix](https://peptideagent.ai/peptides/cetrorelix): Human RCT evidence; FDA approved. FDA approved IVF injection (2000) that prevents early ovulation; pregnancy rates similar to older protocols with fewer cases of ovarian overstimulation. - [Secretin](https://peptideagent.ai/peptides/secretin): Human RCT evidence; FDA approved. FDA approved diagnostic peptide for pancreatic function and gastrinoma testing; randomized trials found no benefit in autism. ## Recent regulatory events - 2026-09-21 WADA: WADA publishes the 2027 Prohibited List (https://peptideagent.ai/regulatory/tesamorelin, https://peptideagent.ai/regulatory/sermorelin, https://peptideagent.ai/regulatory/cjc-1295, https://peptideagent.ai/regulatory/ipamorelin, https://peptideagent.ai/regulatory/ghrp-2, https://peptideagent.ai/regulatory/ghrp-6, https://peptideagent.ai/regulatory/hexarelin, https://peptideagent.ai/regulatory/mk-677, https://peptideagent.ai/regulatory/aod-9604, https://peptideagent.ai/regulatory/igf-1-lr3, https://peptideagent.ai/regulatory/peg-mgf, https://peptideagent.ai/regulatory/tb-500, https://peptideagent.ai/regulatory/hcg, https://peptideagent.ai/regulatory/gonadorelin, https://peptideagent.ai/regulatory/kisspeptin-10, https://peptideagent.ai/regulatory/ace-031, https://peptideagent.ai/regulatory/insulin, https://peptideagent.ai/regulatory/desmopressin, https://peptideagent.ai/regulatory/bpc-157, https://peptideagent.ai/regulatory/mots-c) - 2026-09-18 FDA: FDA warning letter treats GLP-1 plus vitamin combinations as essentially copies (https://peptideagent.ai/regulatory/semaglutide, https://peptideagent.ai/regulatory/tirzepatide) - 2026-08-28 FDA: FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes (https://peptideagent.ai/regulatory/tirzepatide) - 2026-08-19 State board: Mississippi medical, nursing, and pharmacy boards bar research-grade peptides () - 2026-08-01 Other: Louisiana Act 374 on peptide compounding takes effect () - 2026-07-24 PCAC: PCAC votes against adding DSIP to the 503A bulks list (https://peptideagent.ai/regulatory/dsip) - 2026-07-23 PCAC: PCAC recommends six peptides for the 503A bulks list (https://peptideagent.ai/regulatory/bpc-157, https://peptideagent.ai/regulatory/kpv, https://peptideagent.ai/regulatory/tb-500, https://peptideagent.ai/regulatory/mots-c, https://peptideagent.ai/regulatory/semax, https://peptideagent.ai/regulatory/epitalon) - 2026-04-30 FDA: FDA proposes to keep semaglutide, tirzepatide and liraglutide off the 503B bulks list (https://peptideagent.ai/regulatory/semaglutide, https://peptideagent.ai/regulatory/tirzepatide, https://peptideagent.ai/regulatory/liraglutide) - 2026-04-15 FDA: FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2 (https://peptideagent.ai/regulatory/bpc-157, https://peptideagent.ai/regulatory/aod-9604, https://peptideagent.ai/regulatory/cjc-1295, https://peptideagent.ai/regulatory/dihexa, https://peptideagent.ai/regulatory/dsip, https://peptideagent.ai/regulatory/epitalon, https://peptideagent.ai/regulatory/ghk-cu, https://peptideagent.ai/regulatory/ipamorelin, https://peptideagent.ai/regulatory/kpv, https://peptideagent.ai/regulatory/ll-37, https://peptideagent.ai/regulatory/melanotan-ii, https://peptideagent.ai/regulatory/mots-c, https://peptideagent.ai/regulatory/peg-mgf, https://peptideagent.ai/regulatory/selank, https://peptideagent.ai/regulatory/semax, https://peptideagent.ai/regulatory/thymosin-alpha-1, https://peptideagent.ai/regulatory/tb-500) - 2026-03-19 FDA: FDA approves a 7.2 mg Wegovy dose for chronic weight management (https://peptideagent.ai/regulatory/semaglutide) - 2026-03-19 FDA: FDA approves Imcivree (setmelanotide) for acquired hypothalamic obesity (https://peptideagent.ai/regulatory/setmelanotide) - 2026-01-01 WADA: WADA 2026 Prohibited List takes effect (https://peptideagent.ai/regulatory/tesamorelin, https://peptideagent.ai/regulatory/sermorelin, https://peptideagent.ai/regulatory/cjc-1295, https://peptideagent.ai/regulatory/ipamorelin, https://peptideagent.ai/regulatory/ghrp-2, https://peptideagent.ai/regulatory/ghrp-6, https://peptideagent.ai/regulatory/hexarelin, https://peptideagent.ai/regulatory/mk-677, https://peptideagent.ai/regulatory/aod-9604, https://peptideagent.ai/regulatory/igf-1-lr3, https://peptideagent.ai/regulatory/peg-mgf, https://peptideagent.ai/regulatory/tb-500, https://peptideagent.ai/regulatory/hcg, https://peptideagent.ai/regulatory/gonadorelin, https://peptideagent.ai/regulatory/kisspeptin-10, https://peptideagent.ai/regulatory/ace-031, https://peptideagent.ai/regulatory/insulin, https://peptideagent.ai/regulatory/desmopressin, https://peptideagent.ai/regulatory/bpc-157, https://peptideagent.ai/regulatory/mots-c) - 2025-12 FDA: FDA approves oral semaglutide (Wegovy tablets) for weight management (https://peptideagent.ai/regulatory/semaglutide) - 2025-09 FDA: FDA grants accelerated approval of elamipretide for Barth syndrome (https://peptideagent.ai/regulatory/ss-31) - 2025-08-15 FDA: FDA grants accelerated approval of Wegovy for MASH with fibrosis (https://peptideagent.ai/regulatory/semaglutide) - 2025-05-22 FDA: 503B grace period for compounded semaglutide ends (https://peptideagent.ai/regulatory/semaglutide) - 2025-04-22 FDA: 503A grace period for compounded semaglutide ends (https://peptideagent.ai/regulatory/semaglutide) - 2025-03-19 FDA: 503B grace period for compounded tirzepatide ends (https://peptideagent.ai/regulatory/tirzepatide) - 2025-02-21 FDA: FDA declares the semaglutide shortage resolved (https://peptideagent.ai/regulatory/semaglutide) - 2025-02-18 FDA: 503A grace period for compounded tirzepatide ends (https://peptideagent.ai/regulatory/tirzepatide) - 2025-01-28 FDA: FDA approves Ozempic for chronic kidney disease in type 2 diabetes (https://peptideagent.ai/regulatory/semaglutide) - 2025-01-01 WADA: WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times (https://peptideagent.ai/regulatory/tesamorelin, https://peptideagent.ai/regulatory/sermorelin, https://peptideagent.ai/regulatory/cjc-1295, https://peptideagent.ai/regulatory/ipamorelin, https://peptideagent.ai/regulatory/ghrp-2, https://peptideagent.ai/regulatory/ghrp-6, https://peptideagent.ai/regulatory/hexarelin, https://peptideagent.ai/regulatory/mk-677, https://peptideagent.ai/regulatory/aod-9604, https://peptideagent.ai/regulatory/igf-1-lr3, https://peptideagent.ai/regulatory/peg-mgf, https://peptideagent.ai/regulatory/tb-500, https://peptideagent.ai/regulatory/hcg, https://peptideagent.ai/regulatory/gonadorelin, https://peptideagent.ai/regulatory/kisspeptin-10, https://peptideagent.ai/regulatory/ace-031, https://peptideagent.ai/regulatory/insulin, https://peptideagent.ai/regulatory/desmopressin, https://peptideagent.ai/regulatory/bpc-157) - 2024-12-20 FDA: FDA approves Zepbound for obstructive sleep apnea in adults with obesity (https://peptideagent.ai/regulatory/tirzepatide) - 2024-12-19 FDA: FDA reaffirms the tirzepatide shortage is resolved and sets grace periods (https://peptideagent.ai/regulatory/tirzepatide) - 2024-12 FDA: FDA approves the first generic liraglutide injection (https://peptideagent.ai/regulatory/liraglutide) ## State legality Each line: jurisdiction, telehealth, asynchronous prescribing, compounded GLP-1 access, answer-first summary. State facts cite the state statute or rule and the pharmacy board; items pending verification are labeled on the page. - [Federal law (United States)](https://peptideagent.ai/legal/federal): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Federal law sets the floor for every state: an FDA approved peptide (semaglutide, tirzepatide, tesamorelin, bremelanotide) can be prescribed and dispensed anywhere in the country, and a compounded peptide can only be… - [Alabama](https://peptideagent.ai/legal/alabama): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes, with conditions. An Alabama resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Alabama-licensed physician, including through telehealth under the 2022 telehealth… - [Alaska](https://peptideagent.ai/legal/alaska): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. An Alaska resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Alaska-licensed provider, including by telehealth under AS 08.64.364 (physicians) and the 2022… - [Arizona](https://peptideagent.ai/legal/arizona): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. An Arizona resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Arizona-licensed provider or from an out-of-state provider registered under A.R.S. - [Arkansas](https://peptideagent.ai/legal/arkansas): Telehealth allowed; Async not allowed; Compounded GLP-1 limited. Yes, with a stricter first-visit rule than most states. An Arkansas resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Arkansas-licensed provider, including by… - [California](https://peptideagent.ai/legal/california): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A California resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a California-licensed prescriber, including by asynchronous telehealth: Business and Professions Code… - [Colorado](https://peptideagent.ai/legal/colorado): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Colorado resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Colorado-licensed provider, including by telehealth, because Colorado law treats telehealth as the… - [Connecticut](https://peptideagent.ai/legal/connecticut): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Connecticut resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Connecticut-licensed provider, including by telehealth under Connecticut General Statutes section… - [Delaware](https://peptideagent.ai/legal/delaware): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Delaware resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription through telehealth under Title 24, chapter 60 of the Delaware Code, from a Delaware-licensed provider or… - [Florida](https://peptideagent.ai/legal/florida): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Florida resident can legally obtain FDA approved peptides such as semaglutide and tirzepatide from any Florida-licensed prescriber, including by telehealth, and can obtain a compounded peptide when it is… - [Georgia](https://peptideagent.ai/legal/georgia): Telehealth allowed; Async not allowed; Compounded GLP-1 limited. Yes, but Georgia is one of the stricter telehealth states. A Georgia resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Georgia-licensed provider, but Georgia Composite… - [Hawaii](https://peptideagent.ai/legal/hawaii): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Hawaii resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Hawaii-licensed physician, including by telehealth under Hawaii Revised Statutes section 453-1.3, but… - [Idaho](https://peptideagent.ai/legal/idaho): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. An Idaho resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Idaho-licensed provider, including through virtual care under the Idaho Virtual Care Access Act (Idaho… - [Illinois](https://peptideagent.ai/legal/illinois): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. An Illinois resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Illinois-licensed provider, including by telehealth under the Illinois Telehealth Act (225 ILCS… - [Indiana](https://peptideagent.ai/legal/indiana): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. An Indiana resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Indiana-licensed prescriber, including by telehealth under Indiana Code 25-1-9.5, which allows the… - [Iowa](https://peptideagent.ai/legal/iowa): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. An Iowa resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Iowa-licensed physician, including by telemedicine under Iowa Board of Medicine rule 481-655.9, which… - [Kansas](https://peptideagent.ai/legal/kansas): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Kansas resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Kansas-licensed provider, including by telemedicine under the Kansas Telemedicine Act (K.S.A. - [Kentucky](https://peptideagent.ai/legal/kentucky): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes, but Kentucky's Board of Pharmacy has been unusually explicit about GLP-1 copies. - [Louisiana](https://peptideagent.ai/legal/louisiana): Telehealth allowed; Async not allowed; Compounded GLP-1 limited. Yes. A Louisiana resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a physician licensed to practice medicine or telemedicine in Louisiana under La. R.S. - [Maine](https://peptideagent.ai/legal/maine): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Maine resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Maine-licensed prescriber, including by telehealth, and can obtain a compounded peptide when it is eligible under… - [Maryland](https://peptideagent.ai/legal/maryland): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Maryland resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Maryland-licensed prescriber, including through telehealth, and Maryland's telehealth statute (Health Occupations… - [Massachusetts](https://peptideagent.ai/legal/massachusetts): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Massachusetts resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Massachusetts-licensed prescriber, including through telemedicine, which the Board of Registration in Medicine… - [Michigan](https://peptideagent.ai/legal/michigan): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Michigan resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Michigan-licensed prescriber, including through telehealth, because the Public Health Code (MCL 333.16285) lets a… - [Minnesota](https://peptideagent.ai/legal/minnesota): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Minnesota resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Minnesota-licensed prescriber, including through telehealth. - [Mississippi](https://peptideagent.ai/legal/mississippi): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Mississippi resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Mississippi-licensed physician, including by telemedicine under the Board of Medical Licensure's telemedicine rule… - [Missouri](https://peptideagent.ai/legal/missouri): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Missouri resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Missouri-licensed physician, including by telehealth, but Missouri's telehealth statute (RSMo 191.1146, as amended… - [Montana](https://peptideagent.ai/legal/montana): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Montana resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Montana-licensed prescriber, including by telehealth, which Montana defines broadly (MCA 37-2-305) to include… - [Nebraska](https://peptideagent.ai/legal/nebraska): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Nebraska resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Nebraska-credentialed prescriber, including by telehealth, because Neb. Rev. Stat. - [Nevada](https://peptideagent.ai/legal/nevada): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Nevada resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Nevada-licensed prescriber, including by telehealth, which Nevada defines (NRS 629.515) to include synchronous… - [New Hampshire](https://peptideagent.ai/legal/new-hampshire): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A New Hampshire resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a New Hampshire-licensed prescriber, including by telemedicine; RSA 329:1-d treats an out-of-state physician… - [New Jersey](https://peptideagent.ai/legal/new-jersey): Telehealth allowed; Async not allowed; Compounded GLP-1 limited. Yes. A New Jersey resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a New Jersey-licensed prescriber, including through telemedicine under the Telemedicine and Telehealth Act (P.L.2017… - [New Mexico](https://peptideagent.ai/legal/new-mexico): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A New Mexico resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a New Mexico-licensed prescriber, including by telehealth, which the New Mexico Telehealth Act (NMSA 1978, sections… - [New York](https://peptideagent.ai/legal/new-york): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A New York resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a New York-licensed prescriber, including by telehealth under Public Health Law Article 29-G, which covers… - [North Carolina](https://peptideagent.ai/legal/north-carolina): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A North Carolina resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a North Carolina-licensed prescriber, including by telemedicine; North Carolina has no general telehealth… - [North Dakota](https://peptideagent.ai/legal/north-dakota): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A North Dakota resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a North Dakota-licensed prescriber, including by telemedicine under NDCC 43-17-44, which requires a bona fide… - [Ohio](https://peptideagent.ai/legal/ohio): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. An Ohio resident can obtain FDA approved peptides such as semaglutide and tirzepatide from an Ohio-licensed prescriber, including by telehealth: Ohio Revised Code 4743.09 and State Medical Board rule 4731-37-01… - [Oklahoma](https://peptideagent.ai/legal/oklahoma): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. An Oklahoma resident can obtain FDA approved peptides such as semaglutide and tirzepatide from any Oklahoma-licensed prescriber, including through telemedicine under the Oklahoma Telemedicine Act and title 59… - [Oregon](https://peptideagent.ai/legal/oregon): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. An Oregon resident can obtain FDA approved peptides such as semaglutide and tirzepatide from any prescriber licensed by the Oregon Medical Board or the relevant Oregon licensing board, including through… - [Pennsylvania](https://peptideagent.ai/legal/pennsylvania): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Pennsylvania resident can obtain FDA approved peptides such as semaglutide and tirzepatide from any Pennsylvania-licensed prescriber, including through telemedicine under Act 42 of 2024, Pennsylvania's… - [Rhode Island](https://peptideagent.ai/legal/rhode-island): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Rhode Island resident can obtain FDA approved peptides such as semaglutide and tirzepatide from any Rhode Island-licensed prescriber, including through telemedicine under Rhode Island General Laws section… - [South Carolina](https://peptideagent.ai/legal/south-carolina): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A South Carolina resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a South Carolina-licensed prescriber, including by telemedicine under section 40-47-37 of the South Carolina… - [South Dakota](https://peptideagent.ai/legal/south-dakota): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A South Dakota resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a South Dakota-licensed prescriber, including through telehealth under SDCL chapter 34-52, and can obtain a… - [Tennessee](https://peptideagent.ai/legal/tennessee): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Tennessee resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Tennessee-licensed prescriber, including by telehealth under Tennessee Code section 63-1-155, and can obtain a… - [Texas](https://peptideagent.ai/legal/texas): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Texas resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Texas-licensed prescriber, including by telemedicine under Texas Occupations Code chapter 111, and can obtain a… - [Utah](https://peptideagent.ai/legal/utah): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Utah resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Utah-licensed prescriber, including by telehealth under Utah Code section 26B-4-704, and can obtain a compounded peptide… - [Vermont](https://peptideagent.ai/legal/vermont): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Vermont resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a prescriber authorized to practice in Vermont, including by telemedicine or store-and-forward means under 18 V.S.A. - [Virginia](https://peptideagent.ai/legal/virginia): Telehealth allowed; Async allowed; Compounded GLP-1 limited. Yes. A Virginia resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Virginia-licensed prescriber, including by telemedicine under the bona fide practitioner-patient relationship rules… - [Washington](https://peptideagent.ai/legal/washington): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Washington resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Washington-licensed prescriber, including by telehealth under the Uniform Telehealth Act (chapter 18.134 RCW… - [West Virginia](https://peptideagent.ai/legal/west-virginia): Telehealth allowed; Async not allowed; Compounded GLP-1 limited. Yes, with stricter telehealth rules than most states. A West Virginia resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a West Virginia-licensed physician, but under West Virginia Code… - [Wisconsin](https://peptideagent.ai/legal/wisconsin): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Wisconsin resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Wisconsin-licensed prescriber, including by telehealth under Medical Examining Board rule chapter Med 24, and can… - [Wyoming](https://peptideagent.ai/legal/wyoming): Telehealth allowed; Async unclear; Compounded GLP-1 limited. Yes. A Wyoming resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Wyoming-licensed physician, including by telemedicine, which Wyoming Statutes section 33-26-102(a)(xxix) defines as… ## Conditions - [Tendon injury and tendinopathy](https://peptideagent.ai/conditions/tendon-injury): Tendon injuries heal slowly because tendon tissue has low blood supply and cell turnover. - [Obesity and chronic weight management](https://peptideagent.ai/conditions/obesity): GLP-1 based peptides are the only peptides with large randomized trials for weight loss. - [Type 2 diabetes](https://peptideagent.ai/conditions/type-2-diabetes): Several peptide drugs are FDA approved for type 2 diabetes, including insulin, GLP-1 receptor agonists, tirzepatide, and pramlintide. - [Muscle recovery and injury](https://peptideagent.ai/conditions/muscle-recovery): Peptides marketed for muscle recovery include BPC-157, TB-500, PEG-MGF, IGF-1 LR3, and growth hormone secretagogues. - [Skin aging and cosmetic repair](https://peptideagent.ai/conditions/skin-aging): GHK-Cu (copper peptide) is the best studied peptide for skin, with cell and small human cosmetic studies showing increased collagen synthesis and improved skin appearance when applied topically. - [Sexual dysfunction](https://peptideagent.ai/conditions/sexual-dysfunction): Bremelanotide (PT-141) is FDA approved for hypoactive sexual desire disorder in premenopausal women, based on two randomized trials. - [Cognitive decline and nootropic use](https://peptideagent.ai/conditions/cognitive-decline): Semax, selank, dihexa, cerebrolysin, and related compounds are marketed for cognition. Cerebrolysin has small clinical trials in stroke and dementia, mostly outside the United States. - [Sleep disorders](https://peptideagent.ai/conditions/sleep): DSIP (delta sleep-inducing peptide) is the only peptide marketed specifically for sleep; its human studies are small and decades old, and FDA's advisory committee voted against adding it to the 503A… - [Wound healing](https://peptideagent.ai/conditions/wound-healing): Peptides studied for wound healing include GHK-Cu, BPC-157, TB-500, and LL-37. GHK-Cu and LL-37 have small human wound studies; BPC-157 and TB-500 have only animal data. - [Growth hormone deficiency and GH secretagogue use](https://peptideagent.ai/conditions/growth-hormone-deficiency): Tesamorelin is FDA approved to reduce abdominal fat in HIV associated lipodystrophy, and sermorelin was previously approved for pediatric GH deficiency. - [Inflammation and inflammatory bowel disease](https://peptideagent.ai/conditions/inflammation): KPV, thymosin alpha-1, LL-37, VIP, and BPC-157 are marketed as anti-inflammatory peptides. Thymosin alpha-1 has human trials in hepatitis and sepsis outside the United States. - [Longevity and healthy aging](https://peptideagent.ai/conditions/longevity): No peptide has been shown to extend human lifespan. MOTS-c, humanin, and SS-31 (elamipretide) are mitochondrial peptides with rodent data and, for elamipretide, human trials in mitochondrial… - [Cardiovascular risk reduction](https://peptideagent.ai/conditions/cardiovascular-risk): Three GLP-1 receptor agonists have lowered major adverse cardiovascular events in large outcome trials: semaglutide (26% in SUSTAIN-6 and 20% in SELECT), liraglutide (13% in LEADER), and dulaglutide… - [Chronic kidney disease](https://peptideagent.ai/conditions/chronic-kidney-disease): Semaglutide is the only peptide with a dedicated kidney outcome trial: in FLOW, semaglutide 1 mg weekly lowered the risk of major kidney disease events by 24% in people with type 2 diabetes and… - [Fatty liver disease (MASLD and MASH)](https://peptideagent.ai/conditions/fatty-liver-disease): Semaglutide 2.4 mg received FDA accelerated approval in August 2025 for MASH with moderate to advanced liver fibrosis, after the ESSENCE trial showed steatohepatitis resolution in 62.9% of patients… - [Obstructive sleep apnea](https://peptideagent.ai/conditions/obstructive-sleep-apnea): Tirzepatide (Zepbound) is the first drug FDA approved for obstructive sleep apnea, for moderate to severe OSA in adults with obesity (December 2024). - [Type 1 diabetes](https://peptideagent.ai/conditions/type-1-diabetes): Insulin is the essential treatment for type 1 diabetes, and in the DCCT intensive insulin therapy reduced the development and progression of eye, kidney, and nerve complications. - [Insulin resistance and prediabetes](https://peptideagent.ai/conditions/insulin-resistance): Lifestyle change is the best proven intervention: in the Diabetes Prevention Program, intensive lifestyle change cut progression to type 2 diabetes by 58% and metformin by 31%. - [Fat loss and body composition](https://peptideagent.ai/conditions/fat-loss): The peptides with proven fat loss are FDA approved: GLP-1 based drugs produced about 15 to 21% mean weight loss in obesity trials, and tesamorelin cut visceral fat by about 15% in HIV associated… - [Male hypogonadism (low testosterone)](https://peptideagent.ai/conditions/hypogonadism): Testosterone replacement is the standard treatment for confirmed male hypogonadism in men not seeking fertility. - [Infertility and assisted reproduction](https://peptideagent.ai/conditions/infertility): Several peptide drugs are standard, FDA approved tools in fertility care. GnRH antagonists (ganirelix, cetrorelix) prevent premature ovulation during IVF with live birth rates similar to long… - [Erectile dysfunction](https://peptideagent.ai/conditions/erectile-dysfunction): PDE5 inhibitors such as sildenafil and tadalafil are first line for erectile dysfunction. - [Osteoporosis](https://peptideagent.ai/conditions/osteoporosis): Teriparatide and abaloparatide are FDA approved bone building peptides that cut new vertebral fractures by roughly 65 to 86% versus placebo in postmenopausal osteoporosis, and teriparatide… - [Inflammatory bowel disease (Crohn disease and ulcerative colitis)](https://peptideagent.ai/conditions/inflammatory-bowel-disease): No peptide is approved or has published human trials for Crohn disease or ulcerative colitis. KPV and BPC-157, the peptides most marketed for gut inflammation, reduced colitis only in rodent models. - [Irritable bowel syndrome](https://peptideagent.ai/conditions/irritable-bowel-syndrome): Linaclotide, a guanylate cyclase-C agonist peptide, is FDA approved for IBS with constipation; in phase 3 trials about 34% of patients met the combined pain and bowel movement endpoint versus 14% to… - [Hair loss (androgenetic alopecia)](https://peptideagent.ai/conditions/hair-loss): Minoxidil and finasteride are the proven treatments for pattern hair loss. Copper peptide GHK-Cu is widely sold in hair serums based on cell and animal work on hair follicles, but no controlled… - [Anxiety disorders](https://peptideagent.ai/conditions/anxiety): Selank is the only peptide with clinical studies in anxiety, all from Russia and none placebo controlled; it is approved in Russia but not in the United States. - [Depression](https://peptideagent.ai/conditions/depression): No peptide has shown benefit for depression in a controlled human trial. Selank and semax are sometimes marketed for mood, but their human studies are in anxiety and stroke and their brain effects… - [Stroke recovery](https://peptideagent.ai/conditions/stroke-recovery): Cerebrolysin is the most studied peptide in stroke, but the evidence is mixed: a 1,070 patient trial missed its primary endpoint, a Cochrane review found no mortality benefit and a possible rise in… - [Traumatic brain injury](https://peptideagent.ai/conditions/traumatic-brain-injury): No drug, peptide or otherwise, is FDA approved to improve recovery after traumatic brain injury. - [Peripheral and small fiber neuropathy](https://peptideagent.ai/conditions/neuropathy): ARA 290 (cibinetide), a peptide engineered from erythropoietin, improved neuropathic symptoms and corneal nerve fiber measures in small placebo controlled trials in sarcoidosis and type 2 diabetes… - [Immune support and immune deficiency](https://peptideagent.ai/conditions/immune-function): Thymosin alpha-1 is the only immune peptide with substantial human trial data, including controlled trials in chronic hepatitis B and severe sepsis, and it is approved in more than 30 countries but… - [Autoimmune disease](https://peptideagent.ai/conditions/autoimmune-disease): No peptide is approved to treat an autoimmune disease. The only controlled human data are two older placebo controlled trials of nonathymulin in rheumatoid arthritis and ARA 290 trials for nerve… - [HIV associated lipodystrophy](https://peptideagent.ai/conditions/hiv-lipodystrophy): Tesamorelin (Egrifta) is FDA approved to reduce excess abdominal fat in adults with HIV associated lipodystrophy. - [Muscle wasting and sarcopenia](https://peptideagent.ai/conditions/muscle-wasting): No peptide is approved to treat sarcopenia or muscle wasting. MK-677 and the myostatin blocker ACE-031 increased lean mass in human trials without clear gains in strength or function, and both… - [Osteoarthritis](https://peptideagent.ai/conditions/osteoarthritis): No peptide has been shown to rebuild cartilage. Semaglutide 2.4 mg reduced knee osteoarthritis pain in people with obesity in the STEP 9 trial, alongside 13.7% weight loss, and retatrutide is being… - [Chronic pain](https://peptideagent.ai/conditions/chronic-pain): Ziconotide (Prialt), a synthetic cone snail peptide delivered by an implanted intrathecal pump, is the only peptide FDA approved for pain, reserved for severe chronic pain that has failed other… - [Mitochondrial disease and dysfunction](https://peptideagent.ai/conditions/mitochondrial-dysfunction): Elamipretide (SS-31) received FDA accelerated approval in September 2025 for Barth syndrome, a rare inherited mitochondrial disease, but it missed its primary endpoints in the larger MMPOWER-3 trial… - [Acromegaly](https://peptideagent.ai/conditions/acromegaly): Somatostatin analog peptides, octreotide and lanreotide, are the standard FDA approved medical treatment for acromegaly, normalizing growth hormone and IGF-1 in roughly half of patients in pooled… - [Advanced prostate cancer](https://peptideagent.ai/conditions/prostate-cancer): GnRH peptide drugs are the backbone of androgen deprivation therapy for advanced prostate cancer: the agonists leuprolide and triptorelin and the antagonist degarelix all reach castrate testosterone… ## Comparisons - [AOD-9604 vs 5-Amino-1MQ](https://peptideagent.ai/compare/aod-9604-vs-5-amino-1mq): Neither is a sound fat loss option: both have only mouse evidence, neither is FDA approved, neither has a lawful compounding basis, and both are prohibited in sport. - [AOD-9604 vs semaglutide](https://peptideagent.ai/compare/aod-9604-vs-semaglutide): Semaglutide is the clear choice for weight loss: it is FDA approved, produced 14.9% average weight loss versus 2.4% on placebo at 68 weeks in STEP 1, and reduced major cardiovascular events by 20%… - [BPC-157 vs ARA-290 (cibinetide)](https://peptideagent.ai/compare/bpc-157-vs-ara-290): ARA-290 has much stronger evidence: four small placebo controlled human trials show it improved neuropathy symptoms and regrew corneal nerve fibers in sarcoidosis and type 2 diabetes. - [BPC-157 vs GHK-Cu](https://peptideagent.ai/compare/bpc-157-vs-ghk-cu): GHK-Cu has the stronger footing: it has small human studies of topical creams for aged and photodamaged skin, and topical GHK-Cu is sold lawfully as a cosmetic ingredient without a prescription. - [BPC-157 vs KPV](https://peptideagent.ai/compare/bpc-157-vs-kpv): Neither BPC-157 nor KPV has a controlled human trial, so neither is proven for gut or tissue healing in people. - [BPC-157 vs TB-500](https://peptideagent.ai/compare/bpc-157-vs-tb-500): Neither BPC-157 nor TB-500 has a controlled human trial of the injectable product, so neither is proven to speed healing in people. - [Cagrilintide vs pramlintide](https://peptideagent.ai/compare/cagrilintide-vs-pramlintide): Both are amylin analogs, but they sit at opposite ends of the pipeline. Pramlintide (Symlin) has been FDA approved since 2005 as a mealtime add-on to insulin, injected before each major meal, and… - [Carnosine vs glutathione](https://peptideagent.ai/compare/carnosine-vs-glutathione): Carnosine has the stronger clinical evidence: meta-analyses of randomized trials found modest reductions in fasting glucose, HbA1c, and waist circumference, mostly in people with metabolic disease… - [Cerebrolysin vs Semax](https://peptideagent.ai/compare/cerebrolysin-vs-semax): Cerebrolysin has much more evidence than semax, including large placebo controlled stroke trials and Cochrane reviews, but that evidence shows a small and uncertain benefit and a possible rise in… - [CJC-1295 vs ipamorelin](https://peptideagent.ai/compare/cjc-1295-vs-ipamorelin): CJC-1295 has human data that ipamorelin lacks: a single injection raised growth hormone 2 to 10 fold for 6 or more days and IGF-1 1.5 to 3 fold for 9 to 11 days in two small randomized trials in… - [Dihexa vs Semax](https://peptideagent.ai/compare/dihexa-vs-semax): Semax is the better supported of the two: it has open label human studies in stroke, it is a registered prescription drug in Russia, and it was recommended for the FDA 503A bulks list in July 2026. - [Dulaglutide vs exenatide](https://peptideagent.ai/compare/dulaglutide-vs-exenatide): Dulaglutide wins on every measure that has been tested. In the AWARD-1 head-to-head trial, once weekly dulaglutide 1.5 mg lowered HbA1c by 1.51 points versus 0.99 with twice daily exenatide at 26… - [Dulaglutide vs mazdutide](https://peptideagent.ai/compare/dulaglutide-vs-mazdutide): Mazdutide beat dulaglutide in two direct trials in Chinese adults with type 2 diabetes. - [Dulaglutide vs retatrutide](https://peptideagent.ai/compare/dulaglutide-vs-retatrutide): In the phase 2 diabetes trial that tested both, retatrutide 8 mg and 12 mg lowered HbA1c by about 2.0 points versus 1.41 with dulaglutide 1.5 mg at 24 weeks, and cut weight by about 17% versus 2.0%… - [Epitalon vs MOTS-c](https://peptideagent.ai/compare/epitalon-vs-mots-c): Epitalon and MOTS-c are tied on the two things that matter most: both have animal only evidence, and both followed the same regulatory path, removed from the FDA Category 2 list on April 15, 2026… - [Epitalon vs thymalin](https://peptideagent.ai/compare/epitalon-vs-thymalin): Neither has a randomized human trial, and both trace back to the same St. Petersburg institute, so the real difference is regulatory: epitalon was removed from the FDA Category 2 list in April 2026… - [Follistatin-344 vs ACE-031 (ramatercept)](https://peptideagent.ai/compare/follistatin-344-vs-ace-031): ACE-031 has the stronger human evidence: randomized trials showed it increased lean mass and thigh muscle volume, but its Duchenne trial was halted for nosebleeds and dilated blood vessels and… - [GHRP-2 vs GHRP-6](https://peptideagent.ai/compare/ghrp-2-vs-ghrp-6): GHRP-2 and GHRP-6 are closely related six amino acid ghrelin receptor agonists that release growth hormone, cortisol, and prolactin and increase hunger. - [Glutathione vs NAD+](https://peptideagent.ai/compare/glutathione-vs-nad-plus): Glutathione and NAD+ sit at the same evidence and regulatory level: small randomized trials show oral forms raise body levels, no trial shows a clinical outcome, and the injectable forms clinics… - [HCG vs gonadorelin](https://peptideagent.ai/compare/hcg-vs-gonadorelin): hCG has the stronger evidence and the only regimen that matches how these drugs are actually used alongside testosterone therapy: it acts directly on the testis, lasts 24 to 36 hours per dose, and a… - [HCG vs kisspeptin-10](https://peptideagent.ai/compare/hcg-vs-kisspeptin-10): hCG is the evidence-backed option: it is FDA approved as Pregnyl, Novarel, and Ovidrel, it has decades of trial and label evidence for male hypogonadotropic hypogonadism and ovulation induction, and… - [Hexarelin vs GHRP-2](https://peptideagent.ai/compare/hexarelin-vs-ghrp-2): Hexarelin and GHRP-2 are sibling synthetic hexapeptides that release growth hormone through the ghrelin receptor, and the one direct comparison in healthy adults found both released more GH than… - [IGF-1 LR3 vs PEG-MGF](https://peptideagent.ai/compare/igf-1-lr3-vs-peg-mgf): Neither IGF-1 LR3 nor PEG-MGF has ever been given to people in a published study, neither has a lawful US source, and both are prohibited in sport. - [Ipamorelin vs GHRP-6](https://peptideagent.ai/compare/ipamorelin-vs-ghrp-6): Ipamorelin was designed as a cleaner GHRP-6: in the 1998 animal study that introduced it, it matched GHRP-6's growth hormone release in pigs without raising ACTH or cortisol. - [Ipamorelin vs MK-677 (ibutamoren)](https://peptideagent.ai/compare/ipamorelin-vs-mk-677): Both activate the ghrelin receptor to release growth hormone, but MK-677 is an oral small molecule with years of randomized human data, while ipamorelin is an injectable peptide with one small IV… - [Kisspeptin-10 vs gonadorelin](https://peptideagent.ai/compare/kisspeptin-10-vs-gonadorelin): Gonadorelin is the better supported and the only lawfully obtainable option of the two. - [KPV vs LL-37](https://peptideagent.ai/compare/kpv-vs-ll-37): LL-37 is the only one of the two with human trials, but those tested a topical gel on venous leg ulcers, and the larger phase IIb trial missed its primary endpoint. KPV has only mouse colitis data. - [Leuprolide vs degarelix](https://peptideagent.ai/compare/leuprolide-vs-degarelix): Both are FDA approved injections that lower testosterone to castrate levels for advanced prostate cancer, and in their direct 610 patient trial they were equally effective at 1 year (96.4% versus… - [Liraglutide vs cagrilintide](https://peptideagent.ai/compare/liraglutide-vs-cagrilintide): In the phase 2 trial that included both, once weekly cagrilintide 4.5 mg produced 10.8% weight loss at 26 weeks versus 9.0% with once daily liraglutide 3.0 mg, a statistically significant 1.8 point… - [Liraglutide vs dulaglutide](https://peptideagent.ai/compare/liraglutide-vs-dulaglutide): For type 2 diabetes the two are close: in the AWARD-6 head-to-head trial, once weekly dulaglutide 1.5 mg lowered HbA1c by 1.42 points versus 1.36 for once daily liraglutide 1.8 mg, meeting… - [Liraglutide vs exenatide](https://peptideagent.ai/compare/liraglutide-vs-exenatide): Liraglutide beat exenatide in both head-to-head trials: it lowered HbA1c by 1.12 points versus 0.79 against twice daily exenatide in LEAD-6, and by 1.48 versus 1.28 against once weekly exenatide in… - [Liraglutide vs setmelanotide](https://peptideagent.ai/compare/liraglutide-vs-setmelanotide): These drugs treat different people. Liraglutide is a GLP-1 agonist approved for common obesity and type 2 diabetes, with 8.4 kg average weight loss at 56 weeks in SCALE. - [Melanotan I (afamelanotide) vs Melanotan II](https://peptideagent.ai/compare/melanotan-i-vs-melanotan-ii): Melanotan I is the regulated one: as afamelanotide (Scenesse) it is an FDA approved implant for adults with erythropoietic protoporphyria, backed by two randomized phase 3 trials. - [MOTS-c vs humanin](https://peptideagent.ai/compare/mots-c-vs-humanin): MOTS-c and humanin are both mitochondrial derived peptides with animal only evidence, so neither has a proven human benefit; the practical difference is regulatory. - [MOTS-c vs SS-31 (elamipretide)](https://peptideagent.ai/compare/mots-c-vs-ss-31): SS-31 (elamipretide) has the stronger evidence and regulatory standing: it has been tested in randomized human trials and received FDA accelerated approval as Forzinity for Barth syndrome in… - [NAD+ vs MOTS-c](https://peptideagent.ai/compare/nad-plus-vs-mots-c): NAD+ has the stronger human evidence, but mostly for oral precursors: randomized trials show nicotinamide riboside raises blood NAD+ and nicotinamide mononucleotide improved muscle insulin… - [Octreotide vs lanreotide](https://peptideagent.ai/compare/octreotide-vs-lanreotide): Octreotide and lanreotide are FDA approved somatostatin analogs that act on the same receptors (subtypes 2 and 5) and perform similarly in acromegaly, so the choice usually depends on formulation… - [P21 vs Dihexa](https://peptideagent.ai/compare/p21-vs-dihexa): Neither P21 nor dihexa has ever been tested in people, neither has a lawful US source, and both are prohibited in sport as non-approved substances. - [Pinealon vs epitalon](https://peptideagent.ai/compare/pinealon-vs-epitalon): Pinealon (Glu-Asp-Arg) and epitalon (Ala-Glu-Asp-Gly) are short synthetic peptides from the same St. Petersburg institute. - [PT-141 (bremelanotide) vs Melanotan II](https://peptideagent.ai/compare/pt-141-vs-melanotan-ii): PT-141 is the clear choice: as bremelanotide (Vyleesi) it is FDA approved for low sexual desire in premenopausal women on the strength of two phase 3 trials with 1,267 women, and it can be… - [PT-141 vs oxytocin](https://peptideagent.ai/compare/pt-141-vs-oxytocin): For low sexual desire, the reason people compare these two, PT-141 (bremelanotide) is the only one with an FDA indication and randomized trial evidence: two 24 week phase 3 trials in 1,267… - [Retatrutide vs mazdutide](https://peptideagent.ai/compare/retatrutide-vs-mazdutide): Retatrutide has produced the larger weight loss: 28.3% at 12 mg over 80 weeks in the TRIUMPH-1 phase 3 trial (manufacturer topline), versus 14.0% at 6 mg over 48 weeks for mazdutide in GLORY-1 and… - [Retatrutide vs survodutide](https://peptideagent.ai/compare/retatrutide-vs-survodutide): Retatrutide has produced much larger weight loss: 24.2% at 48 weeks on 12 mg in its phase 2 trial, versus 12.2% to 13.0% at 76 weeks for survodutide in the phase 3 SYNCHRONIZE-1 trial. - [Selank vs Noopept](https://peptideagent.ai/compare/selank-vs-noopept): Selank and Noopept are both Russian medicines with only small open label human studies, and neither has a clear lawful US channel. - [Semaglutide vs cagrilintide](https://peptideagent.ai/compare/semaglutide-vs-cagrilintide): Semaglutide is an FDA approved GLP-1 drug with proven weight loss (14.9% at 68 weeks in STEP 1) and cardiovascular benefit, while cagrilintide is an investigational amylin analog that produced 10.8%… - [Semaglutide vs dulaglutide](https://peptideagent.ai/compare/semaglutide-vs-dulaglutide): Semaglutide (Ozempic) beat dulaglutide (Trulicity) directly in SUSTAIN 7: at matched dose tiers it lowered HbA1c by 1.5 and 1.8 points versus 1.1 and 1.4 for dulaglutide, and cut weight by 4.6 and… - [Semaglutide vs exenatide](https://peptideagent.ai/compare/semaglutide-vs-exenatide): Semaglutide beat exenatide directly in SUSTAIN 3: once weekly semaglutide 1 mg lowered HbA1c by 1.5 points versus 0.9 for once weekly exenatide 2 mg and cut weight by 5.6 kg versus 1.9 kg over 56… - [Semaglutide vs liraglutide](https://peptideagent.ai/compare/semaglutide-vs-liraglutide): Semaglutide (Wegovy, Ozempic) produces roughly twice the weight loss of liraglutide (Saxenda, Victoza) in the only direct obesity trial: 15.8% versus 6.4% of body weight at 68 weeks in STEP 8, with… - [Semaglutide vs mazdutide](https://peptideagent.ai/compare/semaglutide-vs-mazdutide): In the only head-to-head trial, DREAMS-3 in 349 Chinese adults with type 2 diabetes and obesity, mazdutide 6 mg beat semaglutide 1 mg: 48.0% versus 21.0% reached both an HbA1c under 7% and at least… - [Semaglutide vs retatrutide](https://peptideagent.ai/compare/semaglutide-vs-retatrutide): Semaglutide is FDA approved, available by prescription, and backed by trials in tens of thousands of people, including a proven reduction in cardiovascular events (SELECT). - [Semaglutide vs setmelanotide](https://peptideagent.ai/compare/semaglutide-vs-setmelanotide): Semaglutide treats common obesity and type 2 diabetes, with 14.9% weight loss in STEP 1 and a 20% cut in cardiovascular events in SELECT. - [Semaglutide vs survodutide](https://peptideagent.ai/compare/semaglutide-vs-survodutide): Semaglutide is the better supported and the only available choice: it is FDA approved, produced 14.9% weight loss in STEP 1, and cut cardiovascular events by 20% in SELECT. - [Semaglutide vs tirzepatide](https://peptideagent.ai/compare/semaglutide-vs-tirzepatide): Tirzepatide (Zepbound, Mounjaro) produces more weight loss than semaglutide (Wegovy, Ozempic) in the only direct obesity trial: 20.2% versus 13.7% of body weight at 72 weeks in SURMOUNT-5, and it… - [Semax vs Noopept](https://peptideagent.ai/compare/semax-vs-noopept): Semax and Noopept are both Russian nootropics with only small open label human studies, but they reach users very differently. - [Semax vs Selank](https://peptideagent.ai/compare/semax-vs-selank): Semax and selank are sister Russian heptapeptides with the same weak evidence base, small open label studies published in Russian, but they are used for different things: semax for stroke recovery… - [Sermorelin vs CJC-1295](https://peptideagent.ai/compare/sermorelin-vs-cjc-1295): Sermorelin is the better choice of the two GHRH analogs because it is the only one with a prior FDA approval, human trials that measured something beyond hormone levels, and a pathway by which 503A… - [Sermorelin vs ipamorelin](https://peptideagent.ai/compare/sermorelin-vs-ipamorelin): Sermorelin has the stronger case: it was once FDA approved (Geref), it has small human trials showing higher growth hormone and IGF-1, and many 503A pharmacies still compound it because FDA found… - [Sermorelin vs MK-677 (ibutamoren)](https://peptideagent.ai/compare/sermorelin-vs-mk-677): Sermorelin is the more defensible choice: it is a GHRH analog that once held FDA approval, it is not on any FDA Category 2 list, and it can be compounded by a licensed 503A pharmacy on a prescription. - [Sermorelin vs tesamorelin](https://peptideagent.ai/compare/sermorelin-vs-tesamorelin): Both are growth hormone releasing hormone analogs, but tesamorelin has far stronger evidence and a current FDA approval: in two phase 3 trials of 806 people with HIV and excess abdominal fat, it cut… - [Survodutide vs mazdutide](https://peptideagent.ai/compare/survodutide-vs-mazdutide): Survodutide and mazdutide are both once weekly GLP-1 and glucagon dual agonists. Mazdutide is further along: approved in China for weight management and type 2 diabetes, with 14.0% weight loss at 48… - [TB-500 vs GHK-Cu](https://peptideagent.ai/compare/tb-500-vs-ghk-cu): GHK-Cu has the better evidence and the easier legal path for its main use: small human studies support topical GHK-Cu creams for aged skin, and those creams are sold lawfully as cosmetics. - [Teriparatide vs abaloparatide](https://peptideagent.ai/compare/teriparatide-vs-abaloparatide): Both are FDA approved daily injections that build bone through the PTH1 receptor, and both sharply reduce vertebral fractures in randomized trials, so the choice depends on the patient. - [Tesamorelin vs CJC-1295](https://peptideagent.ai/compare/tesamorelin-vs-cjc-1295): Both are growth hormone releasing hormone analogs, but only tesamorelin is an approved drug: as Egrifta it cut visceral fat by 15.4% relative to placebo at 26 weeks in phase 3 trials of 806 adults… - [Tesamorelin vs ipamorelin](https://peptideagent.ai/compare/tesamorelin-vs-ipamorelin): Tesamorelin is an FDA approved growth hormone releasing hormone analog (Egrifta WR and Egrifta SV) that reduced visceral fat by 15.4% relative to placebo in phase 3 trials of 806 people with HIV. - [Tesamorelin vs MK-677 (ibutamoren)](https://peptideagent.ai/compare/tesamorelin-vs-mk-677): Tesamorelin is the clear choice: it is an FDA approved GHRH analog with phase 3 trials showing a 15.4% reduction in visceral fat in HIV lipodystrophy and a 37% relative reduction in liver fat in a… - [Tesamorelin vs retatrutide](https://peptideagent.ai/compare/tesamorelin-vs-retatrutide): These are different drugs for different goals. Tesamorelin is an FDA approved growth hormone releasing hormone analog that targets visceral fat: it cut belly fat inside the abdomen by 15.4% relative… - [Tesofensine vs semaglutide](https://peptideagent.ai/compare/tesofensine-vs-semaglutide): Semaglutide is the better choice: it is FDA approved, its weight loss is proven in large phase 3 trials (14.9% versus 2.4% on placebo at 68 weeks in STEP 1), and it reduced major cardiovascular… - [Thymosin alpha-1 vs TB-500 (thymosin beta-4)](https://peptideagent.ai/compare/thymosin-alpha-1-vs-tb-500): Despite the shared name, these are unrelated peptides with different jobs: thymosin alpha-1 is an immune modulator with randomized trials in hepatitis B and sepsis and approval abroad as Zadaxin… - [Thymosin alpha-1 vs thymulin](https://peptideagent.ai/compare/thymosin-alpha-1-vs-thymulin): Thymosin alpha-1 has far more human evidence and real world use: randomized trials in chronic hepatitis B and severe sepsis, and approval as Zadaxin (thymalfasin) in more than 30 countries. - [Tirzepatide vs cagrilintide](https://peptideagent.ai/compare/tirzepatide-vs-cagrilintide): Tirzepatide is FDA approved and produced 20.9% weight loss at 15 mg in SURMOUNT-1. - [Tirzepatide vs dulaglutide](https://peptideagent.ai/compare/tirzepatide-vs-dulaglutide): Tirzepatide is the stronger drug for glucose and weight, and it now has a direct cardiovascular outcomes trial against dulaglutide: in SURPASS-CVOT (13,165 analyzed adults with type 2 diabetes and… - [Tirzepatide vs liraglutide](https://peptideagent.ai/compare/tirzepatide-vs-liraglutide): Tirzepatide produces far more weight loss than liraglutide in their respective trials: 20.9% at 15 mg over 72 weeks in SURMOUNT-1 versus about 8% at 3.0 mg over 56 weeks in SCALE, and it is injected… - [Tirzepatide vs mazdutide](https://peptideagent.ai/compare/tirzepatide-vs-mazdutide): Tirzepatide is FDA approved and produced 20.9% weight loss at 72 weeks on 15 mg in SURMOUNT-1; mazdutide is a GLP-1 and glucagon dual agonist developed mainly in China that produced 14.0% at 48… - [Tirzepatide vs retatrutide](https://peptideagent.ai/compare/tirzepatide-vs-retatrutide): Tirzepatide (Zepbound, Mounjaro) is the one you can actually be prescribed: it is FDA approved for type 2 diabetes, chronic weight management, and obstructive sleep apnea, with 20.9% weight loss at… - [Tirzepatide vs survodutide](https://peptideagent.ai/compare/tirzepatide-vs-survodutide): Tirzepatide has the larger weight loss and the stronger evidence base: 15.0% to 20.9% at 72 weeks in SURMOUNT-1 versus 12.2% to 13.0% at 76 weeks for survodutide in SYNCHRONIZE-1, plus FDA approval… ## Cost - [Semaglutide cost](https://peptideagent.ai/cost/semaglutide): about $149 to $1,349 per month without insurance, by channel; verified 2026-09-27. - [Tirzepatide cost](https://peptideagent.ai/cost/tirzepatide): about $275 to $1,112 per month without insurance, by channel; verified 2026-09-27. - [Liraglutide cost](https://peptideagent.ai/cost/liraglutide): about $112 to $1,349 per month without insurance, by channel; verified 2026-09-27. - [Retatrutide cost](https://peptideagent.ai/cost/retatrutide): prices by channel; verified 2026-09-23. - [Dulaglutide cost](https://peptideagent.ai/cost/dulaglutide): about $389 to $1,007 per month without insurance, by channel; verified 2026-09-27. - [Exenatide cost](https://peptideagent.ai/cost/exenatide): prices by channel; verified 2026-09-22. - [BPC-157 cost](https://peptideagent.ai/cost/bpc-157): prices by channel; verified 2026-09-23. - [TB-500 (thymosin beta-4) cost](https://peptideagent.ai/cost/tb-500): prices by channel; verified 2026-09-23. - [GHK-Cu cost](https://peptideagent.ai/cost/ghk-cu): prices by channel; verified 2026-09-23. - [KPV cost](https://peptideagent.ai/cost/kpv): prices by channel; verified 2026-09-23. - [Epitalon cost](https://peptideagent.ai/cost/epitalon): prices by channel; verified 2026-09-22. - [MOTS-c cost](https://peptideagent.ai/cost/mots-c): prices by channel; verified 2026-09-22. - [SS-31 (elamipretide) cost](https://peptideagent.ai/cost/ss-31): about $66,000 per month without insurance, by channel; verified 2026-09-22. - [NAD+ cost](https://peptideagent.ai/cost/nad-plus): about $79 to $199 per month without insurance, by channel; verified 2026-09-23. - [Glutathione cost](https://peptideagent.ai/cost/glutathione): about $75 to $100 per month without insurance, by channel; verified 2026-09-22. - [Semax cost](https://peptideagent.ai/cost/semax): prices by channel; verified 2026-09-22. - [Selank cost](https://peptideagent.ai/cost/selank): prices by channel; verified 2026-09-22. - [PT-141 (bremelanotide) cost](https://peptideagent.ai/cost/pt-141): about $187 to $224 per month without insurance, by channel; verified 2026-09-22. - [Kisspeptin-10 cost](https://peptideagent.ai/cost/kisspeptin-10): prices by channel; verified 2026-09-22. - [Oxytocin cost](https://peptideagent.ai/cost/oxytocin): about $115 to $135 per month without insurance, by channel; verified 2026-09-22. - [Gonadorelin cost](https://peptideagent.ai/cost/gonadorelin): prices by channel; verified 2026-09-22. - [HCG (human chorionic gonadotropin) cost](https://peptideagent.ai/cost/hcg): prices by channel; verified 2026-09-22. - [Tesamorelin cost](https://peptideagent.ai/cost/tesamorelin): about $10,709 per month without insurance, by channel; verified 2026-09-23. - [Sermorelin cost](https://peptideagent.ai/cost/sermorelin): about $105 to $180 per month without insurance, by channel; verified 2026-09-23. - [Ipamorelin cost](https://peptideagent.ai/cost/ipamorelin): prices by channel; verified 2026-09-23. - [CJC-1295 cost](https://peptideagent.ai/cost/cjc-1295): prices by channel; verified 2026-09-23. - [AOD-9604 cost](https://peptideagent.ai/cost/aod-9604): prices by channel; verified 2026-09-22. - [Tesofensine cost](https://peptideagent.ai/cost/tesofensine): prices by channel; verified 2026-09-22. - [5-Amino-1MQ cost](https://peptideagent.ai/cost/5-amino-1mq): prices by channel; verified 2026-09-22. - [Thymosin alpha-1 cost](https://peptideagent.ai/cost/thymosin-alpha-1): prices by channel; verified 2026-09-22. - [Teriparatide cost](https://peptideagent.ai/cost/teriparatide): prices by channel; verified 2026-09-22. ## API Free, read-only JSON (CC BY 4.0, attribution required), 60 requests per minute per IP. OpenAPI 3.1: https://peptideagent.ai/api/v1/openapi.json - GET https://peptideagent.ai/api/v1/peptides: list of peptides with grades and statuses - GET https://peptideagent.ai/api/v1/peptides/{slug}: full peptide record - GET https://peptideagent.ai/api/v1/regulatory: regulatory events (filter with ?peptide=) - GET https://peptideagent.ai/api/v1/conditions: conditions with graded peptide links - GET https://peptideagent.ai/api/v1/jurisdictions: federal and state records - GET https://peptideagent.ai/api/v1/jurisdictions/{slug}: one state or the federal record - GET https://peptideagent.ai/api/v1/comparisons: head-to-head comparisons - GET https://peptideagent.ai/api/v1/cost: cost entries by channel - GET https://peptideagent.ai/api/v1/search?q=: search peptides by name, alias, or condition - Machine-readable license terms (RSL 1.0) for the API and datasets: https://peptideagent.ai/rsl.xml ## Policies - Author on every page: PeptideAgent (organization). No individual bylines. - Every medical claim cites a primary source; PubMed URLs use the form https://pubmed.ncbi.nlm.nih.gov//. - Dosing is reported from the literature only; the site does not prescribe protocols. - No affiliate relationships with research-use-only vendors. - Corrections and questions: hello@peptideagent.ai